Evidence map›Paper›PMID 31730655›Full record

ArticlePLoS genetics2019

Contribution of Common Genetic Variants to Familial Aggregation of Disease and Implications for Sequencing Studies.

Andrew Schlafly, Ruth M Pfeiffer, Eduardo Nagore, Susana Puig, Donato Calista, Paola Ghiorzo, Chiara Menin, Maria Concetta Fargnoli, Ketty Peris, Lei Song and 4 more

Abstract read
In one paragraph

Article in PLoS genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Andrew SchlaflyIntegrative Tumor Epidemiology Branch: Division of Cancer Epidemiology and GeneticsNational Cancer Institute, Rockville, Maryland, United States of America.
Ruth M PfeifferBiostatistics Branch: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.ORCID 0000-0001-7791-2698
Eduardo NagoreDepartment of Dermatology, Instituto Valenciano de Oncología, València, Spain.ORCID 0000-0003-3433-8707
Susana PuigDermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain.
Donato CalistaDepartment of Dermatology, Maurizio Bufalini Hospital, Cesena, Italy.
Paola GhiorzoGenetics of Rare Cancers, Department of Internal Medicine (DiMI), University of Genoa and Ospedale Policlinico San Martino Genoa, Genoa, Italy.ORCID 0000-0002-3651-8173
Chiara MeninImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.ORCID 0000-0002-8907-772X
Maria Concetta FargnoliDepartment of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.ORCID 0000-0002-7249-2556
Ketty PerisInstitute of Dermatology, Catholic University, Rome, Italy.
Lei SongBiostatistics Branch: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.
Tongwu ZhangIntegrative Tumor Epidemiology Branch: Division of Cancer Epidemiology and GeneticsNational Cancer Institute, Rockville, Maryland, United States of America.
Jianxin ShiBiostatistics Branch: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.
Maria Teresa LandiIntegrative Tumor Epidemiology Branch: Division of Cancer Epidemiology and GeneticsNational Cancer Institute, Rockville, Maryland, United States of America.
Joshua Neil SampsonBiostatistics Branch: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite genetics being accepted as the primary cause of familial aggregation for most diseases, it is still unclear whether afflicted families are likely to share a single highly penetrant rare variant, many minimally penetrant common variants, or a combination of the two types of variants. We therefore use recent estimates of SNP heritability and the liability threshold model to estimate the proportion of afflicted families likely to carry a rare, causal variant. We then show that Polygenic Risk Scores (PRS) may be useful for identifying families likely to carry such a rare variant and therefore for prioritizing families to include in sequencing studies with that aim. Specifically, we introduce a new statistic that estimates the proportion of individuals carrying causal rare variants based on the family structure, disease pattern, and PRS of genotyped individuals. Finally, we consider data from the MelaNostrum consortium and show that, despite an estimated PRS heritability of only 0.05 for melanoma, families carrying putative causal variants had a statistically significantly lower PRS, supporting the idea that PRS prioritization may be a useful future tool. However, it will be important to evaluate whether the presence of rare mendelian variants are generally associated with the proposed test statistic or lower PRS in future and larger studies.

Indexed as

Genetic Predisposition to DiseaseSequence Analysis, DNAAllelesGenetic Diseases, InbornGenetic VariationGenome-Wide Association StudyGenotypeHumansMelanomaMultifactorial InheritancePedigreePhenotypePolymorphism, Single NucleotideRisk Factors

Identifiers

PMID31730655
PMCPMC6881075

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.